Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
Public ClinicalTrials.gov record NCT05203341. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.
Study identification
- NCT ID
- NCT05203341
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 183 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2022
- Primary completion
- Jan 9, 2024
- Completion
- Feb 20, 2024
- Last update posted
- Jan 14, 2025
2022 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | Birmingham | Alabama | 35249 | — |
| Neurocrine Clinical Site | Huntsville | Alabama | 35801 | — |
| Neurocrine Clinical Site | Riverside | California | 92506 | — |
| Neurocrine Clinical Site | San Diego | California | 92103 | — |
| Neurocrine Clinical Site | San Francisco | California | 94143 | — |
| Neurocrine Clinical Site | Torrance | California | 90502 | — |
| Neurocrine Clinical Site | Hartford | Connecticut | 06106 | — |
| Neurocrine Clinical Site | Palmetto Bay | Florida | 33158 | — |
| Neurocrine Clinical Site | Gaithersburg | Maryland | 20877 | — |
| Neurocrine Clinical Site | Weldon Spring | Missouri | 63304 | — |
| Neurocrine Clinical Site | Columbus | Ohio | 43221 | — |
| Neurocrine Clinical Site | North Canton | Ohio | 44720 | — |
| Neurocrine Clinical Site | Oklahoma City | Oklahoma | 73112 | — |
| Neurocrine Clinical Site | Memphis | Tennessee | 38119 | — |
| Neurocrine Clinical Site | Dallas | Texas | 75390 | — |
| Neurocrine Clinical Site | Houston | Texas | 77030 | — |
| Neurocrine Clinical Site | Draper | Utah | 84020 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05203341, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05203341 live on ClinicalTrials.gov.